Q² Solutions and KingMed Partner to Develop In Vitro Diagnostics and Companion Diagnostics in China

Q2 Solutions and KingMed to Develop IVDs and CDx in China


Morrisville, NC – January 23, 2019 – Q2 Solutions, a leading clinical trial laboratory services organization, has partnered with Guangzhou KingMed Diagnostics, a leading independent clinical laboratory in China, to jointly develop in vitro diagnostics (IVD) products and companion diagnostics (CDx) in China and to collaborate to transition IVD products from China to the rest of the world by leveraging the Q2 Solutions global footprint. The partnership combines Q2 Solutions’ advanced technologies and scientific expertise in clinical trial laboratory testing with KingMed’s laboratory, marketing and regulatory expertise in China to promote the development of IVDs.  

Under the strategic cooperation agreement, KingCreate, a KingMed subsidiary focused on developing and commercializing IVD products in China, will become the commercialization solution for Q2 Solutions clients who wish to launch companion diagnostics (CDx) in the China market, to the extent applicable with regulatory norms in China. Additionally, KingCreate will exclusively utilize the Q2 Solutions China laboratory for the testing of IVDs and potential CDx products, and will rely on Q2 Solutions global footprint for any clinical trial testing required to obtain regulatory approval under global regulatory bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Q2 Solutions will also enable their biopharmaceutical clients to have access to KingCreate IVD assays.  

“We are excited to extend our relationship with KingMed to bring innovative IVD products to the global market via the KingCreate partnership. Our relationship goes back many years and is firmly rooted in our shared commitment to developing innovative diagnostics tests for patients across the globe.” said Brian O’Dwyer, CEO of Q2 Solutions. “It requires a special partner to navigate the various scientific and logistical considerations that are needed to bring diagnostics and therapeutics to market in China. With KingMed, we have the perfect partner to support our clients and KingCreate in their efforts to deliver effective precision medicines to the right patients.”

"In support of medical examiners, KingMed will give full effort to making use of the advantages of our technology platform and service network in precision diagnosis, promoting diversified business development in clinical trials of new drugs, and advancing precision medicine," said Liang Yaoming, chairman and CEO of KingMed. “The cooperation with Q2 Solutions will be more conducive to introducing the most advanced diagnostic technologies and products. With the business platforms KingMed has developed, we will be able to accurately screen for suitable populations for new drugs, and thus serve patients with standardized large-scale CDx testing.”

About Q2 Solutions
Q2 Solutions is a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions. With a relentless focus on quality and innovation, Q2 Solutions uses its global experience and scientific expertise to transform science and data into actionable medical insights that help customers improve human health. A joint venture of IQVIA and Quest Diagnostics, Q2 Solutions combines the best of each parent organization’s clinical trials laboratory services capabilities to fulfill its mission of treating each sample as if a life depends on it. 

Q2 Solutions has a large presence in China, with central laboratory, bioanalytical, and genomics services in Beijing supporting studies in China for multinational biopharmaceutical companies and serving as a partner to Chinese biopharmaceutical companies conducting Chinese and global studies. Through its Beijing lab, Q2 Solutions has been involved in more than 650 studies involving more than 50,000 patients in Mainland China. To learn more, visit  

About KingMed Diagnostics
Guangzhou KingMed Diagnostics Group Co., Ltd. ( was established in 2003 as the leading independent clinical testing laboratory in China that has been serving over 21,000 medical institutions as our customers. KingMed develops and commercializes an extensive medical, pathological and genomic testing offering with over 2,400 testing items to a wide range of medical and healthcare institutions with its 37 established testing laboratories across China. KingMed made a successful IPO at Shanghai Stock Exchange in 2017.